Chemotherapy Effects - Pipeline Review, H2 2012

Description: Chemotherapy Effects – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Chemotherapy Effects - Pipeline Review, H2 2012', provides an overview of the Chemotherapy Effects therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. 'Chemotherapy Effects - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of Chemotherapy Effects therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chemotherapy Effects Therapeutic Products under Development, Key Players in Chemotherapy Effects Therapeutics, Chemotherapy Effects Pipeline Overview, Chemotherapy Effects Pipeline, Chemotherapy Effects Pipeline Assessment

Contents:

- List of Tables 8
- List of Figures 10
- Introduction 11
REPORT COVERAGE 11
Chemotherapy Effects Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Chemotherapy Effects 13
Chemotherapy Effects Therapeutics under Development by Companies 15
Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Chemotherapy Effects Therapeutics – Products under Development by Companies 30
Chemotherapy Effects Therapeutics – Products under Investigation by Universities/Institutes 36
Companies Involved in Chemotherapy Effects Therapeutics Development 39
Kyowa Hakko Kirin Co., Ltd. 39
Amgen Inc. 40
Adherex Technologies Inc. 41
BioDelivery Sciences International, Inc. 42
Merck & Co., Inc. 43
Lentigen Corporation 44
Reliance Life Sciences Pvt. Ltd. 45
A.P. Pharma, Inc. 46
Aphios Corporation 47
Axcan Pharma Inc. 48
Daewoong Pharmaceutical Co., Ltd. 49
Dong-A Pharmaceutical Co., Ltd. 50
Dr. Reddy's Laboratories Limited 51
Maxygen, Inc. 52
Teva Pharmaceutical Industries Limited 53
Sandoz Inc. 54
CEL-SCI Corporation 55
Zosano Pharma, Inc. 56
3SBio Inc. 57
EpiCept Corporation 58
Hana Biosciences, Inc. 59
La Jolla Pharmaceutical Company 60
BTG International Ltd 61
Mundipharma International Limited 62
ProMetic Life Sciences Inc. 63
Lipoxen PLC 64
Pluristem Therapeutics Inc. 65
DARA BioSciences, Inc. 66
LTT Bio-Pharma Co., Ltd. 67
Eurofarma 97
Neumedicines Inc. 98
Varinel, Inc. 99
Acacia Pharma Ltd. 100
Advancell 101
Chemotherapy Effects – Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Route of Administration 104
Assessment by Molecule Type 106
Drug Profiles 109
Nplate - Drug Profile 109
Rolapitant - Drug Profile 111
MAXY-G34 - Drug Profile 112
Sotatercept - Drug Profile 113
Sodium thiosulfate - Drug Profile 115
Menadione Topical Lotion - Drug Profile 117
EUR 1025 - Drug Profile 118
SyB D-0701 - Drug Profile 119
MDPK67b - Drug Profile 120
NT-13317 - Drug Profile 122
Clonidine Lauriad - Drug Profile 123
Easyef - Drug Profile 124
Multikine - Drug Profile 125
TZP-201 - Drug Profile 127
Sustained Release G-CSF - Drug Profile 128
KRNS500 - Drug Profile 129
NuPIAO - Drug Profile 131
Sancuso - Drug Profile 132
Voraxaze - Drug Profile 133
APF530 - Drug Profile 134
AmiKet - Drug Profile 135
RHB-102 - Drug Profile 136
PEG-GCSF - Drug Profile 137
LG631 - Drug Profile 138
AVI-014 - Drug Profile 140
ZP1846 - Drug Profile 141
PBI-1402 - Drug Profile 142
Neugranin - Drug Profile 143
INDUS82020 - Drug Profile 145
SPI-205 - Drug Profile 146
Zindol - Drug Profile 193
Bendavia - Drug Profile 194
Ecallantide - Drug Profile 196
Recombinant Glycopegylated GCSCF - Drug Profile 197
Aprepitant - Drug Profile 198
Aprepitant - Drug Profile 199
KRNS321 - Drug Profile 200
Sildenafil - Drug Profile 201
ATH008 - Drug Profile 202
APD421 - Drug Profile 203
CXB909 - Drug Profile 204
Sorafenib + Betamethasone - Drug Profile 205
Sorafenib + Betamethasone - Drug Profile 206
Carboplatin + Gluthathione + Paclitaxel - Drug Profile 207
Emend + Kevatril + Dexamethasone - Drug Profile 209
Vitamin B6 - Drug Profile 210
Emend - Drug Profile 211
Aprepitant + Palonosetron + Dexamethasone - Drug Profile 212
CR-3294 - Drug Profile 213
PN-401 - Drug Profile 214
WR-2721 - Drug Profile 216
TPW-146 - Drug Profile 217
Gabapentin - Drug Profile 218
Palonosetron - Drug Profile 219
SPI-1005 - Drug Profile 220
SPI-3005 - Drug Profile 222
ALM101 - Drug Profile 223
WBI-2100 - Drug Profile 224
WBI-2100 + Gemcitabine - Drug Profile 225
WBI-2100 + Dacarbazine - Drug Profile 226
WBI-2100 + Taxol - Drug Profile 227
Netupitant-Palonosetron FDC - Drug Profile 228
HemaMax - Drug Profile 230
Flucinonide - Drug Profile 231
Dexamethasone + Palonosetron - Drug Profile 232
Dexpanthenol - Drug Profile 233
PanCyte + Erythropoietin - Drug Profile 234
Filgrastim Injection (G-CSF) - Drug Profile 235
Palonosetron + Dexamethasone + Aprepitant - Drug Profile 236
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyowa Hakko Kirin Co., Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Amgen Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Adherex Technologies Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Lentigen Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>Reliance Life Sciences Pvt. Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>A.P. Pharma, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Aphiios Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>Axcan Pharma Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Daewoong Pharmaceutical Co., Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Dong-A Pharmaceutical Co., Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Dr. Reddy's Laboratories Limited</td>
<td>2012</td>
</tr>
<tr>
<td>Maxygen, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Limited</td>
<td>2012</td>
</tr>
<tr>
<td>Sandoz Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>CEL-SCI Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>Zosano Pharma, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>3SBio Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>EpiCept Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>Hana Biosciences, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>La Jolla Pharmaceutical Company</td>
<td>2012</td>
</tr>
<tr>
<td>BTG International Ltd</td>
<td>2012</td>
</tr>
<tr>
<td>Mundipharma International Limited</td>
<td>2012</td>
</tr>
<tr>
<td>ProMetic Life Sciences Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Lipoxen PLC.</td>
<td>2012</td>
</tr>
<tr>
<td>Pluristem Therapeutics Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>DARA BioSciences, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>LTT Bio-Pharma Co., Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Uni-Bio Science Group Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>ProStrakan Group plc</td>
<td>2012</td>
</tr>
<tr>
<td>BioAlliance Pharma SA</td>
<td>2012</td>
</tr>
<tr>
<td>AGI Therapeutics plc</td>
<td>2012</td>
</tr>
<tr>
<td>Teikoku Pharma USA, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>SymBio Pharmaceuticals Limited</td>
<td>2012</td>
</tr>
<tr>
<td>Cellerant Therapeutics, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Acceleron Pharma, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Neurotune AG.</td>
<td>2012</td>
</tr>
<tr>
<td>Med Discovery SA</td>
<td>2012</td>
</tr>
<tr>
<td>Helsinn Healthcare S.A.</td>
<td>2012</td>
</tr>
<tr>
<td>Wellstat Therapeutics Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>Trophos SA.</td>
<td>2012</td>
</tr>
<tr>
<td>Tranzyme Pharma, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Indus Biotech Private Limited</td>
<td>2012</td>
</tr>
<tr>
<td>Synageva BioPharma Corp.</td>
<td>2012</td>
</tr>
<tr>
<td>Phage Biotechnology Corporation</td>
<td>2012</td>
</tr>
<tr>
<td>CeNeRx BioPharma, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Inimex Pharmaceuticals, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Bolder Biotechnology, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Shin Nippon Biomedical Laboratories, Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Velichem Biotech Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>USV Limited.,</td>
<td>2012</td>
</tr>
<tr>
<td>Sound Pharmaceuticals, Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Krenitsky Pharmaceuticals Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Almac Discovery Ltd.</td>
<td>2012</td>
</tr>
<tr>
<td>Pfenex Inc.,</td>
<td>2012</td>
</tr>
<tr>
<td>Therapure Biopharma Inc.</td>
<td>2012</td>
</tr>
<tr>
<td>Eurofarma, H2 2012 106</td>
<td></td>
</tr>
<tr>
<td>Neumedicines Inc., H2 2012 107</td>
<td></td>
</tr>
<tr>
<td>Varinel, Inc., H2 2012 108</td>
<td></td>
</tr>
<tr>
<td>Acacia Pharma Ltd.,</td>
<td>2012</td>
</tr>
</tbody>
</table>

**Note:** The list above contains the names of companies and institutions involved in research and development activities as of H2 2012. The sequence of the list may not reflect the order of importance or contribution to the field.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chemotherapy Effects - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2216738/
Office Code: SCD27FAF

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________________________ Last Name: _______________________________________
Email Address: * ______________________________________
Job Title: __________________________________________
Organisation: ________________________________________
Address: __________________________________________
City: ______________________________________________
Postal / Zip Code: __________________________________
Country: __________________________________________
Phone Number: ______________________________________
Fax Number: ________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World